SAINT LAURENT, QUEBEC--(Marketwire - April 08, 2008) - IntelGenx Corp. (OTCBB: IGXT) ("IntelGenx" or the "Company") and Cary Pharmaceuticals ("Cary") today ratified the Definitive Agreement ("Agreement") originally signed on November 5, 2007 to jointly develop and commercialize Cary's oral antidepressant ("CPI-300" or the "Product") using IntelGenx's proprietary oral delivery technology.
